메뉴 건너뛰기




Volumn 28, Issue 6, 2014, Pages 1055-1071

Transplantation in chronic lymphocytic leukemia. Does it still matter in the era of novel targeted therapies?

Author keywords

Allogeneic hematopoietic stem cell transplantation; Chronic lymphocytic leukemia; GvHD; GvL; High risk patients; Novel substances

Indexed keywords

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL EFFECTIVENESS; GENE MUTATION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HIGH RISK PATIENT; HUMAN; MEDICAL SOCIETY; MINIMAL RESIDUAL DISEASE; MOLECULARLY TARGETED THERAPY; PATIENT MONITORING; PRACTICE GUIDELINE; REDUCED INTENSITY CONDITIONING; REVIEW; RISK ASSESSMENT; TREATMENT INDICATION; ALLOTRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PROCEDURES; RISK FACTOR; SURVIVAL; TREATMENT OUTCOME;

EID: 84912115250     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2014.08.005     Document Type: Review
Times cited : (2)

References (123)
  • 3
    • 84912100970 scopus 로고    scopus 로고
    • 1975-2009 (vintage 2009 populations) National Cancer Institute, Bethesda (MD), based on November 2011 SEER data submission, posted to the SEER web site. Available at: N. Howlader, A.M. Noone, M. Krapcho (Eds.)
    • SEER cancer statistics review, 1975-2009 (vintage 2009 populations) 2012, National Cancer Institute, Bethesda (MD), based on November 2011 SEER data submission, posted to the SEER web site. Available at:. http://seer.cancer.gov/csr/1975_2009_pops09/, N. Howlader, A.M. Noone, M. Krapcho (Eds.).
    • (2012)
  • 4
    • 51649093353 scopus 로고    scopus 로고
    • Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
    • Tam C.S., O'Brien S., Wierda W., et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008, 112:975-980.
    • (2008) Blood , vol.112 , pp. 975-980
    • Tam, C.S.1    O'Brien, S.2    Wierda, W.3
  • 5
    • 77957664665 scopus 로고    scopus 로고
    • Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
    • Hallek M., Fischer K., Fingerle-Rowson G., et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010, 376:1164-1174.
    • (2010) Lancet , vol.376 , pp. 1164-1174
    • Hallek, M.1    Fischer, K.2    Fingerle-Rowson, G.3
  • 6
    • 0034727833 scopus 로고    scopus 로고
    • Genomic aberrations and survival in chronic lymphocytic leukemia
    • Döhner H., Stilgenbauer S., Benner A., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. NEngl J Med 2000, 343:1910-1916.
    • (2000) NEngl J Med , vol.343 , pp. 1910-1916
    • Döhner, H.1    Stilgenbauer, S.2    Benner, A.3
  • 7
    • 79551504914 scopus 로고    scopus 로고
    • TP53 mutation and survival in chronic lymphocytic leukemia
    • Zenz T., Eichhorst B., Busch R., et al. TP53 mutation and survival in chronic lymphocytic leukemia. JClin Oncol 2010, 28:4473-4479.
    • (2010) JClin Oncol , vol.28 , pp. 4473-4479
    • Zenz, T.1    Eichhorst, B.2    Busch, R.3
  • 8
    • 84883743048 scopus 로고    scopus 로고
    • Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab
    • Fink A.M., Bottcher S., Ritgen M., et al. Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab. Leukemia 2013, 27:1949-1952.
    • (2013) Leukemia , vol.27 , pp. 1949-1952
    • Fink, A.M.1    Bottcher, S.2    Ritgen, M.3
  • 9
    • 84896323847 scopus 로고    scopus 로고
    • Treatment of older patients with chronic lymphocytic leukemia: key questions and current answers
    • Shanafelt T. Treatment of older patients with chronic lymphocytic leukemia: key questions and current answers. Hematology Am Soc Hematol Educ Program 2013, 2013:158-167.
    • (2013) Hematology Am Soc Hematol Educ Program , vol.2013 , pp. 158-167
    • Shanafelt, T.1
  • 10
    • 84904818973 scopus 로고    scopus 로고
    • Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: final analysis of an open-label phase II study
    • Hillmen P., Gribben J.G., Follows G.A., et al. Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: final analysis of an open-label phase II study. JClin Oncol 2014, 32:1236-1241.
    • (2014) JClin Oncol , vol.32 , pp. 1236-1241
    • Hillmen, P.1    Gribben, J.G.2    Follows, G.A.3
  • 11
    • 84898486579 scopus 로고    scopus 로고
    • Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients
    • Foà R., Del Giudice I., Cuneo A., et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. Am J Hematol 2014, 89:480-486.
    • (2014) Am J Hematol , vol.89 , pp. 480-486
    • Foà, R.1    Del Giudice, I.2    Cuneo, A.3
  • 12
    • 84894552888 scopus 로고    scopus 로고
    • Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions
    • Goede V., Fischer K., Busch R., et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. NEngl J Med 2014, 370:1101-1110.
    • (2014) NEngl J Med , vol.370 , pp. 1101-1110
    • Goede, V.1    Fischer, K.2    Busch, R.3
  • 13
    • 77950502126 scopus 로고    scopus 로고
    • Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia
    • Wierda W.G., Kipps T.J., Mayer J., et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. JClin Oncol 2010, 28:1749-1755.
    • (2010) JClin Oncol , vol.28 , pp. 1749-1755
    • Wierda, W.G.1    Kipps, T.J.2    Mayer, J.3
  • 14
    • 79959190996 scopus 로고    scopus 로고
    • Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia
    • Wierda W.G., Kipps T.J., Durig J., et al. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood 2011, 117:6450-6458.
    • (2011) Blood , vol.117 , pp. 6450-6458
    • Wierda, W.G.1    Kipps, T.J.2    Durig, J.3
  • 15
    • 81055148076 scopus 로고    scopus 로고
    • Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study
    • Wierda W.G., Padmanabhan S., Chan G.W., et al. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood 2011, 118:5126-5129.
    • (2011) Blood , vol.118 , pp. 5126-5129
    • Wierda, W.G.1    Padmanabhan, S.2    Chan, G.W.3
  • 16
    • 84879748062 scopus 로고    scopus 로고
    • Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia
    • Byrd J.C., Furman R.R., Coutre S.E., et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. NEngl J Med 2013, 369:32-42.
    • (2013) NEngl J Med , vol.369 , pp. 32-42
    • Byrd, J.C.1    Furman, R.R.2    Coutre, S.E.3
  • 17
    • 84912122613 scopus 로고    scopus 로고
    • Aphase 1b/2 study evaluating activity and tolerability of the BTK inhibitor ibrutinib in combination with ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases
    • Jaglowski S.M., Jones J.A., Flynn J.M., et al. Aphase 1b/2 study evaluating activity and tolerability of the BTK inhibitor ibrutinib in combination with ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. ASCO Meeting Abstracts 2014, 32:7009.
    • (2014) ASCO Meeting Abstracts , vol.32 , pp. 7009
    • Jaglowski, S.M.1    Jones, J.A.2    Flynn, J.M.3
  • 18
    • 84904252369 scopus 로고    scopus 로고
    • Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia
    • Byrd J.C., Brown J.R., O'Brien S., et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. NEngl J Med 2014, 371:213-223.
    • (2014) NEngl J Med , vol.371 , pp. 213-223
    • Byrd, J.C.1    Brown, J.R.2    O'Brien, S.3
  • 19
    • 84906855910 scopus 로고    scopus 로고
    • Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study
    • Burger J.A., Keating M.J., Wierda W.G., et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol 2014, 15(10):1090-1099.
    • (2014) Lancet Oncol , vol.15 , Issue.10 , pp. 1090-1099
    • Burger, J.A.1    Keating, M.J.2    Wierda, W.G.3
  • 20
    • 84901712964 scopus 로고    scopus 로고
    • Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia
    • Brown J.R., Byrd J.C., Coutre S.E., et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood 2014, 123:3390-3397.
    • (2014) Blood , vol.123 , pp. 3390-3397
    • Brown, J.R.1    Byrd, J.C.2    Coutre, S.E.3
  • 21
    • 84896692766 scopus 로고    scopus 로고
    • Idelalisib and rituximab in relapsed chronic lymphocytic leukemia
    • Furman R.R., Sharman J.P., Coutre S.E., et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. NEngl J Med 2014, 370:997-1007.
    • (2014) NEngl J Med , vol.370 , pp. 997-1007
    • Furman, R.R.1    Sharman, J.P.2    Coutre, S.E.3
  • 22
    • 84863116430 scopus 로고    scopus 로고
    • Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase i study of navitoclax in patients with relapsed or refractory disease
    • Roberts A.W., Seymour J.F., Brown J.R., et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase i study of navitoclax in patients with relapsed or refractory disease. JClin Oncol 2012, 30:488-496.
    • (2012) JClin Oncol , vol.30 , pp. 488-496
    • Roberts, A.W.1    Seymour, J.F.2    Brown, J.R.3
  • 23
    • 84902183019 scopus 로고    scopus 로고
    • Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib
    • Woyach J.A., Furman R.R., Liu T.M., et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. NEngl J Med 2014, 370:2286-2294.
    • (2014) NEngl J Med , vol.370 , pp. 2286-2294
    • Woyach, J.A.1    Furman, R.R.2    Liu, T.M.3
  • 24
    • 84912125997 scopus 로고    scopus 로고
    • Immunotherapeutic strategies including transplantation: eradication of disease
    • Gribben J.G., Riches J.C. Immunotherapeutic strategies including transplantation: eradication of disease. Hematology Am Soc Hematol Educ Program 2013, 2013:151-157.
    • (2013) Hematology Am Soc Hematol Educ Program , vol.2013 , pp. 151-157
    • Gribben, J.G.1    Riches, J.C.2
  • 25
    • 58149384550 scopus 로고    scopus 로고
    • Graft-versus-leukemia effects of transplantation and donor lymphocytes
    • Kolb H.J. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008, 112:4371-4383.
    • (2008) Blood , vol.112 , pp. 4371-4383
    • Kolb, H.J.1
  • 26
    • 0022646788 scopus 로고
    • Localization of gene for human p53 tumour antigen to band 17p13
    • Isobe M., Emanuel B.S., Givol D., et al. Localization of gene for human p53 tumour antigen to band 17p13. Nature 1986, 320:84-85.
    • (1986) Nature , vol.320 , pp. 84-85
    • Isobe, M.1    Emanuel, B.S.2    Givol, D.3
  • 27
    • 54049141334 scopus 로고    scopus 로고
    • Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up
    • Zenz T., Kröber A., Scherer K., et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 2008, 112:3322-3329.
    • (2008) Blood , vol.112 , pp. 3322-3329
    • Zenz, T.1    Kröber, A.2    Scherer, K.3
  • 28
    • 58249117812 scopus 로고    scopus 로고
    • The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype
    • Dicker F., Herholz H., Schnittger S., et al. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia 2008, 23:117-124.
    • (2008) Leukemia , vol.23 , pp. 117-124
    • Dicker, F.1    Herholz, H.2    Schnittger, S.3
  • 29
    • 70349231440 scopus 로고    scopus 로고
    • De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience
    • Tam C.S., Shanafelt T.D., Wierda W.G., et al. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood 2009, 114:957-964.
    • (2009) Blood , vol.114 , pp. 957-964
    • Tam, C.S.1    Shanafelt, T.D.2    Wierda, W.G.3
  • 30
    • 84866531516 scopus 로고    scopus 로고
    • Bendamustine in combination with rituximabfor previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
    • Fischer K., Cramer P., Busch R., et al. Bendamustine in combination with rituximabfor previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II Trial of the German Chronic Lymphocytic Leukemia Study Group. JClin Oncol 2012, 30:3209-3216.
    • (2012) JClin Oncol , vol.30 , pp. 3209-3216
    • Fischer, K.1    Cramer, P.2    Busch, R.3
  • 31
    • 79954435811 scopus 로고    scopus 로고
    • Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712
    • Woyach J.A., Ruppert A.S., Heerema N.A., et al. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. JClin Oncol 2011, 29:1349-1355.
    • (2011) JClin Oncol , vol.29 , pp. 1349-1355
    • Woyach, J.A.1    Ruppert, A.S.2    Heerema, N.A.3
  • 32
    • 37649004407 scopus 로고    scopus 로고
    • Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia
    • Hillmen P., Skotnicki A.B., Robak T., et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. JClin Oncol 2007, 25:5616-5623.
    • (2007) JClin Oncol , vol.25 , pp. 5616-5623
    • Hillmen, P.1    Skotnicki, A.B.2    Robak, T.3
  • 33
    • 55749093568 scopus 로고    scopus 로고
    • Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab
    • Zent C.S., Call T.G., Shanafelt T.D., et al. Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Cancer 2008, 113:2110-2118.
    • (2008) Cancer , vol.113 , pp. 2110-2118
    • Zent, C.S.1    Call, T.G.2    Shanafelt, T.D.3
  • 34
    • 84863769805 scopus 로고    scopus 로고
    • Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial
    • Pettitt A.R., Jackson R., Carruthers S., et al. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. JClin Oncol 2012, 30:1647-1655.
    • (2012) JClin Oncol , vol.30 , pp. 1647-1655
    • Pettitt, A.R.1    Jackson, R.2    Carruthers, S.3
  • 35
    • 80052180048 scopus 로고    scopus 로고
    • Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia
    • Parikh S.A., Keating M.J., O'Brien S., et al. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. Blood 2011, 118:2062-2068.
    • (2011) Blood , vol.118 , pp. 2062-2068
    • Parikh, S.A.1    Keating, M.J.2    O'Brien, S.3
  • 36
    • 69849107362 scopus 로고    scopus 로고
    • Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group
    • Stilgenbauer S., Zenz T., Winkler D., et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. JClin Oncol 2009, 27:3994-4001.
    • (2009) JClin Oncol , vol.27 , pp. 3994-4001
    • Stilgenbauer, S.1    Zenz, T.2    Winkler, D.3
  • 37
    • 84902831336 scopus 로고    scopus 로고
    • Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells
    • Zent C.S., Taylor R.P., Lindorfer M.A., et al. Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells. Am J Hematol 2014, 89:757-765.
    • (2014) Am J Hematol , vol.89 , pp. 757-765
    • Zent, C.S.1    Taylor, R.P.2    Lindorfer, M.A.3
  • 38
    • 37149029392 scopus 로고    scopus 로고
    • Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features
    • Bowen D.A., Call T.G., Jenkins G.D., et al. Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma 2007, 48:2412-2417.
    • (2007) Leuk Lymphoma , vol.48 , pp. 2412-2417
    • Bowen, D.A.1    Call, T.G.2    Jenkins, G.D.3
  • 39
    • 80052188111 scopus 로고    scopus 로고
    • Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia
    • Badoux X.C., Keating M.J., Wang X., et al. Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia. Blood 2011, 118:2085-2093.
    • (2011) Blood , vol.118 , pp. 2085-2093
    • Badoux, X.C.1    Keating, M.J.2    Wang, X.3
  • 40
    • 79953072637 scopus 로고    scopus 로고
    • Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL
    • Badoux X.C., Keating M.J., Wang X., et al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 2011, 117:3016-3024.
    • (2011) Blood , vol.117 , pp. 3016-3024
    • Badoux, X.C.1    Keating, M.J.2    Wang, X.3
  • 41
    • 0037092951 scopus 로고    scopus 로고
    • Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study
    • Keating M.J., Flinn I., Jain V., et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002, 99:3554-3561.
    • (2002) Blood , vol.99 , pp. 3554-3561
    • Keating, M.J.1    Flinn, I.2    Jain, V.3
  • 42
    • 38349163290 scopus 로고    scopus 로고
    • Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia
    • Tsimberidou A.M., Wierda W.G., Plunkett W., et al. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. JClin Oncol 2008, 26:196-203.
    • (2008) JClin Oncol , vol.26 , pp. 196-203
    • Tsimberidou, A.M.1    Wierda, W.G.2    Plunkett, W.3
  • 43
    • 84878448458 scopus 로고    scopus 로고
    • Aphase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
    • Brown J.R., Messmer B., Werner L., et al. Aphase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Haematologica 2013, 98:964-970.
    • (2013) Haematologica , vol.98 , pp. 964-970
    • Brown, J.R.1    Messmer, B.2    Werner, L.3
  • 44
    • 33845543049 scopus 로고    scopus 로고
    • Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus
    • Dreger P., Corradini P., Kimby E., et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 2007, 21:12-17.
    • (2007) Leukemia , vol.21 , pp. 12-17
    • Dreger, P.1    Corradini, P.2    Kimby, E.3
  • 45
    • 45149100665 scopus 로고    scopus 로고
    • Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute Working Group 1996 guidelines
    • Hallek M., Cheson B.D., Catovsky D., et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute Working Group 1996 guidelines. Blood 2008, 111:5446-5456.
    • (2008) Blood , vol.111 , pp. 5446-5456
    • Hallek, M.1    Cheson, B.D.2    Catovsky, D.3
  • 46
    • 84860773361 scopus 로고    scopus 로고
    • Risk categories and refractory CLL in the era of chemoimmunotherapy
    • Zenz T., Gribben J.G., Hallek M., et al. Risk categories and refractory CLL in the era of chemoimmunotherapy. Blood 2012, 119:4101-4107.
    • (2012) Blood , vol.119 , pp. 4101-4107
    • Zenz, T.1    Gribben, J.G.2    Hallek, M.3
  • 47
    • 0027225899 scopus 로고
    • Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia
    • Rabinowe S., Soiffer R., Gribben J., et al. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood 1993, 82:1366-1376.
    • (1993) Blood , vol.82 , pp. 1366-1376
    • Rabinowe, S.1    Soiffer, R.2    Gribben, J.3
  • 48
    • 0028289052 scopus 로고
    • Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results
    • Khouri I.F., Keating M.J., Vriesendorp H.M., et al. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. JClin Oncol 1994, 12:748-758.
    • (1994) JClin Oncol , vol.12 , pp. 748-758
    • Khouri, I.F.1    Keating, M.J.2    Vriesendorp, H.M.3
  • 49
    • 0031879197 scopus 로고    scopus 로고
    • Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies
    • Khouri I.F., Keating M., Körbling M., et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. JClin Oncol 1998, 16:2817-2824.
    • (1998) JClin Oncol , vol.16 , pp. 2817-2824
    • Khouri, I.F.1    Keating, M.2    Körbling, M.3
  • 50
    • 0032006125 scopus 로고    scopus 로고
    • Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases
    • Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998, 91:756-763.
    • (1998) Blood , vol.91 , pp. 756-763
    • Slavin, S.1    Nagler, A.2    Naparstek, E.3
  • 51
    • 0035383762 scopus 로고    scopus 로고
    • Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects
    • McSweeney P.A., Niederwieser D., Shizuru J.A., et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001, 97:3390-3400.
    • (2001) Blood , vol.97 , pp. 3390-3400
    • McSweeney, P.A.1    Niederwieser, D.2    Shizuru, J.A.3
  • 52
    • 84902084387 scopus 로고    scopus 로고
    • Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation
    • Passweg J.R., Baldomero H., Peters C., et al. Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation. Bone Marrow Transplant 2014, 49:744-750.
    • (2014) Bone Marrow Transplant , vol.49 , pp. 744-750
    • Passweg, J.R.1    Baldomero, H.2    Peters, C.3
  • 53
    • 77957743452 scopus 로고    scopus 로고
    • Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial
    • Dreger P., Doehner H., Ritgen M., et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 2010, 116:2438-2447.
    • (2010) Blood , vol.116 , pp. 2438-2447
    • Dreger, P.1    Doehner, H.2    Ritgen, M.3
  • 54
    • 54449093967 scopus 로고    scopus 로고
    • Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning
    • Sorror M.L., Storer B.E., Sandmaier B.M., et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. JClin Oncol 2008, 26:4912-4920.
    • (2008) JClin Oncol , vol.26 , pp. 4912-4920
    • Sorror, M.L.1    Storer, B.E.2    Sandmaier, B.M.3
  • 55
    • 55549097826 scopus 로고    scopus 로고
    • Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia with 17p- deletion: a retrospective EBMT analysis
    • Schetelig J., van Biezen A., Brand R., et al. Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia with 17p- deletion: a retrospective EBMT analysis. JClin Oncol 2008, 26:5094-5100.
    • (2008) JClin Oncol , vol.26 , pp. 5094-5100
    • Schetelig, J.1    van Biezen, A.2    Brand, R.3
  • 56
    • 80053901737 scopus 로고    scopus 로고
    • Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome
    • Khouri I.F., Bassett R., Poindexter N., et al. Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome. Cancer 2011, 117:4679-4688.
    • (2011) Cancer , vol.117 , pp. 4679-4688
    • Khouri, I.F.1    Bassett, R.2    Poindexter, N.3
  • 57
    • 84873567955 scopus 로고    scopus 로고
    • Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome
    • Brown J.R., Kim H.T., Armand P., et al. Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome. Leukemia 2013, 27:362-369.
    • (2013) Leukemia , vol.27 , pp. 362-369
    • Brown, J.R.1    Kim, H.T.2    Armand, P.3
  • 58
    • 20644447584 scopus 로고    scopus 로고
    • Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia
    • Moreno C., Villamor N., Colomer D., et al. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. JClin Oncol 2005, 23:3433-3438.
    • (2005) JClin Oncol , vol.23 , pp. 3433-3438
    • Moreno, C.1    Villamor, N.2    Colomer, D.3
  • 59
    • 0038528397 scopus 로고    scopus 로고
    • Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning
    • Dreger P., Brand R., Hansz J., et al. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia 2003, 17:841-848.
    • (2003) Leukemia , vol.17 , pp. 841-848
    • Dreger, P.1    Brand, R.2    Hansz, J.3
  • 60
    • 28844483804 scopus 로고    scopus 로고
    • Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia
    • Gribben J.G., Zahrieh D., Stephans K., et al. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 2005, 106:4389-4396.
    • (2005) Blood , vol.106 , pp. 4389-4396
    • Gribben, J.G.1    Zahrieh, D.2    Stephans, K.3
  • 61
    • 0042130360 scopus 로고    scopus 로고
    • Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group
    • Schetelig J., Thiede C., Bornhauser M., et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. JClin Oncol 2003, 21:2747-2753.
    • (2003) JClin Oncol , vol.21 , pp. 2747-2753
    • Schetelig, J.1    Thiede, C.2    Bornhauser, M.3
  • 62
    • 84879173666 scopus 로고    scopus 로고
    • TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial
    • Dreger P., Schnaiter A., Zenz T., et al. TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial. Blood 2013, 121:3284-3288.
    • (2013) Blood , vol.121 , pp. 3284-3288
    • Dreger, P.1    Schnaiter, A.2    Zenz, T.3
  • 63
    • 84855370035 scopus 로고    scopus 로고
    • SF3B1 and other novel cancer genes in chronic lymphocytic leukemia
    • Wang L., Lawrence M.S., Wan Y., et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. NEngl J Med 2011, 365:2497-2506.
    • (2011) NEngl J Med , vol.365 , pp. 2497-2506
    • Wang, L.1    Lawrence, M.S.2    Wan, Y.3
  • 64
    • 84555171449 scopus 로고    scopus 로고
    • Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia
    • Quesada V., Conde L., Villamor N., et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 2012, 44:47-52.
    • (2012) Nat Genet , vol.44 , pp. 47-52
    • Quesada, V.1    Conde, L.2    Villamor, N.3
  • 65
    • 84901408966 scopus 로고    scopus 로고
    • Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial
    • Stilgenbauer S., Schnaiter A., Paschka P., et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014, 123:3247-3254.
    • (2014) Blood , vol.123 , pp. 3247-3254
    • Stilgenbauer, S.1    Schnaiter, A.2    Paschka, P.3
  • 66
    • 84922546660 scopus 로고    scopus 로고
    • Recurrent mutations refine prognosis in chronic lymphocytic leukemia
    • [Epub ahead of print]
    • Baliakas P., Hadzidimitriou A., Sutton L.A., et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia 2014, [Epub ahead of print].
    • (2014) Leukemia
    • Baliakas, P.1    Hadzidimitriou, A.2    Sutton, L.A.3
  • 67
    • 84873500921 scopus 로고    scopus 로고
    • Rituximab, fludarabine, and total body irradiation as conditioning regimen before allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukemia: long-term prospective multicenter study
    • Michallet M., Socié G., Mohty M., et al. Rituximab, fludarabine, and total body irradiation as conditioning regimen before allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukemia: long-term prospective multicenter study. Exp Hematol 2013, 41:127-133.
    • (2013) Exp Hematol , vol.41 , pp. 127-133
    • Michallet, M.1    Socié, G.2    Mohty, M.3
  • 68
    • 77958020833 scopus 로고    scopus 로고
    • The impact of HLA matching on long-term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: a retrospective study from the EBMT registry
    • Michallet M., Sobh M., Milligan D., et al. The impact of HLA matching on long-term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: a retrospective study from the EBMT registry. Leukemia 2010, 24:1725-1731.
    • (2010) Leukemia , vol.24 , pp. 1725-1731
    • Michallet, M.1    Sobh, M.2    Milligan, D.3
  • 69
    • 84884154021 scopus 로고    scopus 로고
    • Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome
    • Tsimberidou A.M., Wierda W.G., Wen S., et al. Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome. Clin Lymphoma Myeloma Leuk 2013, 13:568-574.
    • (2013) Clin Lymphoma Myeloma Leuk , vol.13 , pp. 568-574
    • Tsimberidou, A.M.1    Wierda, W.G.2    Wen, S.3
  • 70
    • 79551472206 scopus 로고    scopus 로고
    • Subcutaneous alemtuzumab combined with oral dexamethasone, followed by alemtuzumab maintenance or allo-SCT In CLL with 17p- or refractory to fludarabine - interim analysis of the CLL2O trial of the GCLLSG and FCGCLL/MW
    • Stilgenbauer S., Cymbalista F., Leblond V., et al. Subcutaneous alemtuzumab combined with oral dexamethasone, followed by alemtuzumab maintenance or allo-SCT In CLL with 17p- or refractory to fludarabine - interim analysis of the CLL2O trial of the GCLLSG and FCGCLL/MW. ASH Annual Meeting Abstracts 2010, 116:920.
    • (2010) ASH Annual Meeting Abstracts , vol.116 , pp. 920
    • Stilgenbauer, S.1    Cymbalista, F.2    Leblond, V.3
  • 71
    • 84872324740 scopus 로고    scopus 로고
    • Fludarabine with cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with poor-risk chronic lymphocytic leukemia
    • Krejci M., Doubek M., Brychtova Y., et al. Fludarabine with cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with poor-risk chronic lymphocytic leukemia. Ann Hematol 2013, 92:249-254.
    • (2013) Ann Hematol , vol.92 , pp. 249-254
    • Krejci, M.1    Doubek, M.2    Brychtova, Y.3
  • 72
    • 70350090181 scopus 로고    scopus 로고
    • Risk score for outcome after allogeneic hematopoietic stem cell transplantation
    • Gratwohl A., Stern M., Brand R., et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation. Cancer 2009, 115:4715-4726.
    • (2009) Cancer , vol.115 , pp. 4715-4726
    • Gratwohl, A.1    Stern, M.2    Brand, R.3
  • 73
    • 79951513494 scopus 로고    scopus 로고
    • Allogeneic stem cell transplantation for chronic lymphocytic leukemia: lessons to be learned from minimal residual disease studies
    • Boettcher S., Ritgen M., Dreger P. Allogeneic stem cell transplantation for chronic lymphocytic leukemia: lessons to be learned from minimal residual disease studies. Blood Rev 2011, 25:91-96.
    • (2011) Blood Rev , vol.25 , pp. 91-96
    • Boettcher, S.1    Ritgen, M.2    Dreger, P.3
  • 74
    • 21144456107 scopus 로고    scopus 로고
    • Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival
    • Moreton P., Kennedy B., Lucas G., et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. JClin Oncol 2005, 23:2971-2979.
    • (2005) JClin Oncol , vol.23 , pp. 2971-2979
    • Moreton, P.1    Kennedy, B.2    Lucas, G.3
  • 75
    • 84860630561 scopus 로고    scopus 로고
    • Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial
    • Boettcher S., Ritgen M., Fischer K., et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. JClin Oncol 2012, 30:980-988.
    • (2012) JClin Oncol , vol.30 , pp. 980-988
    • Boettcher, S.1    Ritgen, M.2    Fischer, K.3
  • 76
    • 84899708181 scopus 로고    scopus 로고
    • The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy
    • Santacruz R., Villamor N., Aymerich M., et al. The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy. Haematologica 2014, 99:873-880.
    • (2014) Haematologica , vol.99 , pp. 873-880
    • Santacruz, R.1    Villamor, N.2    Aymerich, M.3
  • 77
    • 84902590340 scopus 로고    scopus 로고
    • Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL
    • Strati P., Keating M.J., O'Brien S.M., et al. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood 2014, 123:3727-3732.
    • (2014) Blood , vol.123 , pp. 3727-3732
    • Strati, P.1    Keating, M.J.2    O'Brien, S.M.3
  • 78
    • 66049119568 scopus 로고    scopus 로고
    • Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation
    • Farina L., Carniti C., Dodero A., et al. Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation. Haematologica 2009, 94:654-662.
    • (2009) Haematologica , vol.94 , pp. 654-662
    • Farina, L.1    Carniti, C.2    Dodero, A.3
  • 79
    • 84881478607 scopus 로고    scopus 로고
    • Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia
    • Logan A.C., Zhang B., Narasimhan B., et al. Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia. Leukemia 2013, 27:1659-1665.
    • (2013) Leukemia , vol.27 , pp. 1659-1665
    • Logan, A.C.1    Zhang, B.2    Narasimhan, B.3
  • 80
    • 84873999328 scopus 로고    scopus 로고
    • Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia
    • Richardson S.E., Khan I., Rawstron A., et al. Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia. Br J Haematol 2013, 160:640-648.
    • (2013) Br J Haematol , vol.160 , pp. 640-648
    • Richardson, S.E.1    Khan, I.2    Rawstron, A.3
  • 81
    • 84864996370 scopus 로고    scopus 로고
    • Allogeneic hematopoietic stem cell transplant with reduced-intensity conditioning for chronic lymphocytic leukemia in Sweden: does donor T-cell engraftment 3 months after transplant predict survival?
    • Machaczka M., Johansson J.E., Remberger M., et al. Allogeneic hematopoietic stem cell transplant with reduced-intensity conditioning for chronic lymphocytic leukemia in Sweden: does donor T-cell engraftment 3 months after transplant predict survival?. Leuk Lymphoma 2012, 53:1699-1705.
    • (2012) Leuk Lymphoma , vol.53 , pp. 1699-1705
    • Machaczka, M.1    Johansson, J.E.2    Remberger, M.3
  • 82
    • 27744580700 scopus 로고    scopus 로고
    • Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease
    • Toze C.L., Galal A., Barnett M.J., et al. Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease. Bone Marrow Transplant 2005, 36:825-830.
    • (2005) Bone Marrow Transplant , vol.36 , pp. 825-830
    • Toze, C.L.1    Galal, A.2    Barnett, M.J.3
  • 83
    • 84875763976 scopus 로고    scopus 로고
    • The evolving role of stem cell transplantation in chronic lymphocytic leukemia
    • Dreger P. The evolving role of stem cell transplantation in chronic lymphocytic leukemia. Hematol Oncol Clin North Am 2013, 27:355-369.
    • (2013) Hematol Oncol Clin North Am , vol.27 , pp. 355-369
    • Dreger, P.1
  • 84
    • 79955975797 scopus 로고    scopus 로고
    • Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium
    • Pidala J., Kurland B., Chai X., et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood 2009, 117:4651-4657.
    • (2009) Blood , vol.117 , pp. 4651-4657
    • Pidala, J.1    Kurland, B.2    Chai, X.3
  • 85
    • 84912082586 scopus 로고    scopus 로고
    • Outcome of chronic lymphocytic leukemia (CLL) patients that failed allogeneic stem cell transplantation
    • Benjamini O., Rozovski U., Jain P., et al. Outcome of chronic lymphocytic leukemia (CLL) patients that failed allogeneic stem cell transplantation. Blood ASH Annual Meeting Abstracts 2013, 122:2880.
    • (2013) Blood ASH Annual Meeting Abstracts , vol.122 , pp. 2880
    • Benjamini, O.1    Rozovski, U.2    Jain, P.3
  • 86
    • 79551631475 scopus 로고    scopus 로고
    • Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation
    • Michallet M., Dreger P., Sutton L., et al. Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation. Blood 2010, 117:1516-1521.
    • (2010) Blood , vol.117 , pp. 1516-1521
    • Michallet, M.1    Dreger, P.2    Sutton, L.3
  • 87
    • 79959485796 scopus 로고    scopus 로고
    • Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC
    • Sutton L., Chevret S., Tournilhac O., et al. Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC. Blood 2011, 117:6109-6119.
    • (2011) Blood , vol.117 , pp. 6109-6119
    • Sutton, L.1    Chevret, S.2    Tournilhac, O.3
  • 88
    • 84859472894 scopus 로고    scopus 로고
    • Autologous transplantation in CLL patients with B and C Binet stages: final results of the prospective randomized GOELAMS LLC 98 trial
    • Brion A., Mahe B., Kolb B., et al. Autologous transplantation in CLL patients with B and C Binet stages: final results of the prospective randomized GOELAMS LLC 98 trial. Bone Marrow Transplant 2012, 47:542-548.
    • (2012) Bone Marrow Transplant , vol.47 , pp. 542-548
    • Brion, A.1    Mahe, B.2    Kolb, B.3
  • 89
    • 84861498523 scopus 로고    scopus 로고
    • Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial
    • Dreger P., Doehner H., McClanahan F., et al. Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial. Blood 2012, 119:4851-4859.
    • (2012) Blood , vol.119 , pp. 4851-4859
    • Dreger, P.1    Doehner, H.2    McClanahan, F.3
  • 90
    • 33645085041 scopus 로고    scopus 로고
    • High incidence of myelodysplasia and secondary leukaemia in the UK Medical Research Council Pilot of autografting in chronic lymphocytic leukaemia
    • Milligan D.W., Kochethu G., Dearden C., et al. High incidence of myelodysplasia and secondary leukaemia in the UK Medical Research Council Pilot of autografting in chronic lymphocytic leukaemia. Br J Haematol 2006, 133:173-175.
    • (2006) Br J Haematol , vol.133 , pp. 173-175
    • Milligan, D.W.1    Kochethu, G.2    Dearden, C.3
  • 91
    • 84892871843 scopus 로고    scopus 로고
    • Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies
    • Hallek M. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Blood 2013, 122:3723-3734.
    • (2013) Blood , vol.122 , pp. 3723-3734
    • Hallek, M.1
  • 92
    • 84897490051 scopus 로고    scopus 로고
    • How will B-cell-receptor-targeted therapies change future CLL therapy?
    • Jones J.A., Byrd J.C. How will B-cell-receptor-targeted therapies change future CLL therapy?. Blood 2014, 123:1455-1460.
    • (2014) Blood , vol.123 , pp. 1455-1460
    • Jones, J.A.1    Byrd, J.C.2
  • 93
    • 84899656300 scopus 로고    scopus 로고
    • Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies
    • Davila M., Bouhassira D.G., Park J., et al. Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies. Int J Hematol 2014, 99:361-371.
    • (2014) Int J Hematol , vol.99 , pp. 361-371
    • Davila, M.1    Bouhassira, D.G.2    Park, J.3
  • 94
    • 46749132717 scopus 로고    scopus 로고
    • Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug
    • Ramsay A.G., Johnson A.J., Lee A.M., et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. JClin Invest 2008, 118:2427-2437.
    • (2008) JClin Invest , vol.118 , pp. 2427-2437
    • Ramsay, A.G.1    Johnson, A.J.2    Lee, A.M.3
  • 95
    • 84880276168 scopus 로고    scopus 로고
    • Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL)
    • Shanafelt T.D., Ramsay A.G., Zent C.S., et al. Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL). Blood 2013, 121:4137-4141.
    • (2013) Blood , vol.121 , pp. 4137-4141
    • Shanafelt, T.D.1    Ramsay, A.G.2    Zent, C.S.3
  • 96
    • 84865165316 scopus 로고    scopus 로고
    • Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer
    • Ramsay A.G., Clear A.J., Fatah R., et al. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood 2012, 120:1412-1421.
    • (2012) Blood , vol.120 , pp. 1412-1421
    • Ramsay, A.G.1    Clear, A.J.2    Fatah, R.3
  • 97
    • 84878263355 scopus 로고    scopus 로고
    • Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide
    • Ramsay A.G., Evans R., Kiaii S., et al. Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. Blood 2013, 121:2704-2714.
    • (2013) Blood , vol.121 , pp. 2704-2714
    • Ramsay, A.G.1    Evans, R.2    Kiaii, S.3
  • 98
    • 70349150560 scopus 로고    scopus 로고
    • Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia
    • Aue G., Njuguna N., Tian X., et al. Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia. Haematologica 2009, 94:1266-1273.
    • (2009) Haematologica , vol.94 , pp. 1266-1273
    • Aue, G.1    Njuguna, N.2    Tian, X.3
  • 99
    • 77950966887 scopus 로고    scopus 로고
    • Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway
    • Lapalombella R., Andritsos L., Liu Q., et al. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood 2010, 115:2619-2629.
    • (2010) Blood , vol.115 , pp. 2619-2629
    • Lapalombella, R.1    Andritsos, L.2    Liu, Q.3
  • 100
    • 33947243663 scopus 로고    scopus 로고
    • Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study
    • Chanan-Khan A., Miller K.C., Musial L., et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. JClin Oncol 2006, 24:5343-5349.
    • (2006) JClin Oncol , vol.24 , pp. 5343-5349
    • Chanan-Khan, A.1    Miller, K.C.2    Musial, L.3
  • 101
    • 73949145763 scopus 로고    scopus 로고
    • Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma
    • Witzig T.E., Wiernik P.H., Moore T., et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. JClin Oncol 2009, 27:5404-5409.
    • (2009) JClin Oncol , vol.27 , pp. 5404-5409
    • Witzig, T.E.1    Wiernik, P.H.2    Moore, T.3
  • 102
    • 84875451856 scopus 로고    scopus 로고
    • Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia
    • Badoux X.C., Keating M.J., Wen S., et al. Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. JClin Oncol 2013, 31:584-591.
    • (2013) JClin Oncol , vol.31 , pp. 584-591
    • Badoux, X.C.1    Keating, M.J.2    Wen, S.3
  • 103
    • 45149115902 scopus 로고    scopus 로고
    • Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia
    • Andritsos L.A., Johnson A.J., Lozanski G., et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. JClin Oncol 2008, 26:2519-2525.
    • (2008) JClin Oncol , vol.26 , pp. 2519-2525
    • Andritsos, L.A.1    Johnson, A.J.2    Lozanski, G.3
  • 104
    • 45949100928 scopus 로고    scopus 로고
    • Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia
    • Ferrajoli A., Lee B.N., Schlette E.J., et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008, 111:5291-5297.
    • (2008) Blood , vol.111 , pp. 5291-5297
    • Ferrajoli, A.1    Lee, B.N.2    Schlette, E.J.3
  • 105
    • 79952769640 scopus 로고    scopus 로고
    • Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia
    • Chen C.I., Bergsagel P.L., Paul H., et al. Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. JClin Oncol 2011, 29:1175-1181.
    • (2011) JClin Oncol , vol.29 , pp. 1175-1181
    • Chen, C.I.1    Bergsagel, P.L.2    Paul, H.3
  • 106
    • 80053350801 scopus 로고    scopus 로고
    • Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia
    • Badoux X.C., Keating M.J., Wen S., et al. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood 2011, 118:3489-3498.
    • (2011) Blood , vol.118 , pp. 3489-3498
    • Badoux, X.C.1    Keating, M.J.2    Wen, S.3
  • 107
    • 84886393934 scopus 로고    scopus 로고
    • Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia
    • Strati P., Keating M.J., Wierda W.G., et al. Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia. Blood 2013, 122:734-737.
    • (2013) Blood , vol.122 , pp. 734-737
    • Strati, P.1    Keating, M.J.2    Wierda, W.G.3
  • 108
    • 84863011553 scopus 로고    scopus 로고
    • The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing invitro and invivo
    • Ponader S., Chen S.S., Buggy J.J., et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing invitro and invivo. Blood 2012, 119:1182-1189.
    • (2012) Blood , vol.119 , pp. 1182-1189
    • Ponader, S.1    Chen, S.S.2    Buggy, J.J.3
  • 109
    • 79959404661 scopus 로고    scopus 로고
    • Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
    • Herman S.E., Gordon A.L., Hertlein E., et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011, 117:6287-6296.
    • (2011) Blood , vol.117 , pp. 6287-6296
    • Herman, S.E.1    Gordon, A.L.2    Hertlein, E.3
  • 110
    • 84858636448 scopus 로고    scopus 로고
    • The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia
    • de Rooij M.F., Kuil A., Geest C.R., et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 2012, 119:2590-2594.
    • (2012) Blood , vol.119 , pp. 2590-2594
    • de Rooij, M.F.1    Kuil, A.2    Geest, C.R.3
  • 111
    • 80053345977 scopus 로고    scopus 로고
    • The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
    • Hoellenriegel J., Meadows S.A., Sivina M., et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011, 118:3603-3612.
    • (2011) Blood , vol.118 , pp. 3603-3612
    • Hoellenriegel, J.1    Meadows, S.A.2    Sivina, M.3
  • 112
    • 79955977369 scopus 로고    scopus 로고
    • The role of phosphatidylinositol 3-kinase-delta in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia
    • Herman S.E., Lapalombella R., Gordon A.L., et al. The role of phosphatidylinositol 3-kinase-delta in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia. Blood 2011, 117:4323-4327.
    • (2011) Blood , vol.117 , pp. 4323-4327
    • Herman, S.E.1    Lapalombella, R.2    Gordon, A.L.3
  • 113
    • 84883557418 scopus 로고    scopus 로고
    • Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia
    • Stephens D.M., Ruppert A.S., Maddocks K., et al. Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia. Leuk Res 2013, 37:1195-1199.
    • (2013) Leuk Res , vol.37 , pp. 1195-1199
    • Stephens, D.M.1    Ruppert, A.S.2    Maddocks, K.3
  • 114
    • 84862017961 scopus 로고    scopus 로고
    • Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features
    • Woyach J.A., Lozanski G., Ruppert A.S., et al. Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features. Leukemia 2012, 26:1442-1444.
    • (2012) Leukemia , vol.26 , pp. 1442-1444
    • Woyach, J.A.1    Lozanski, G.2    Ruppert, A.S.3
  • 115
    • 70349438847 scopus 로고    scopus 로고
    • Engineering lymphocyte subsets: tools, trials and tribulations
    • June C.H., Blazar B.R., Riley J.L. Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol 2009, 9:704-716.
    • (2009) Nat Rev Immunol , vol.9 , pp. 704-716
    • June, C.H.1    Blazar, B.R.2    Riley, J.L.3
  • 116
    • 80051720194 scopus 로고    scopus 로고
    • Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia
    • Porter D.L., Levine B.L., Kalos M., et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. NEngl J Med 2011, 365:725-733.
    • (2011) NEngl J Med , vol.365 , pp. 725-733
    • Porter, D.L.1    Levine, B.L.2    Kalos, M.3
  • 117
    • 84863337890 scopus 로고    scopus 로고
    • B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
    • Kochenderfer J.N., Dudley M.E., Feldman S.A., et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012, 119:2709-2720.
    • (2012) Blood , vol.119 , pp. 2709-2720
    • Kochenderfer, J.N.1    Dudley, M.E.2    Feldman, S.A.3
  • 118
    • 80455179612 scopus 로고    scopus 로고
    • Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
    • Brentjens R.J., Riviere I., Park J.H., et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011, 118:4817-4828.
    • (2011) Blood , vol.118 , pp. 4817-4828
    • Brentjens, R.J.1    Riviere, I.2    Park, J.H.3
  • 119
    • 80051775476 scopus 로고    scopus 로고
    • Tcells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia
    • 95ra73
    • Kalos M., Levine B.L., Porter D.L., et al. Tcells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011, 3:95ra73.
    • (2011) Sci Transl Med , vol.3
    • Kalos, M.1    Levine, B.L.2    Porter, D.L.3
  • 120
    • 84876325876 scopus 로고    scopus 로고
    • Chimeric antigen receptor-modified T cells for acute lymphoid leukemia
    • Grupp S.A., Kalos M., Barrett D., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. NEngl J Med 2013, 368:1509-1518.
    • (2013) NEngl J Med , vol.368 , pp. 1509-1518
    • Grupp, S.A.1    Kalos, M.2    Barrett, D.3
  • 121
    • 84890827981 scopus 로고    scopus 로고
    • Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation
    • Kochenderfer J.N., Dudley M.E., Carpenter R.O., et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 2013, 122:4129-4139.
    • (2013) Blood , vol.122 , pp. 4129-4139
    • Kochenderfer, J.N.1    Dudley, M.E.2    Carpenter, R.O.3
  • 122
    • 84891832317 scopus 로고    scopus 로고
    • Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells
    • Xu X.J., Tang Y.M. Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells. Cancer Lett 2014, 343:172-178.
    • (2014) Cancer Lett , vol.343 , pp. 172-178
    • Xu, X.J.1    Tang, Y.M.2
  • 123
    • 84901603046 scopus 로고    scopus 로고
    • The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison
    • Herth I., Dietrich S., Benner A., et al. The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison. Ann Oncol 2014, 25:200-206.
    • (2014) Ann Oncol , vol.25 , pp. 200-206
    • Herth, I.1    Dietrich, S.2    Benner, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.